NASDAQ:PRPO Precipio - PRPO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Precipio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.88 -0.02 (-2.16%) (As of 01/26/2023 04:14 PM ET) Add Compare Share Share Today's Range$0.88▼$0.9450-Day Range$0.50▼$0.9152-Week Range$0.47▼$1.77Volume47,383 shsAverage Volume141,975 shsMarket Capitalization$20.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Precipio MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 3 Articles This WeekInsider TradingAcquiring Shares$25,950 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.45 out of 5 starsMedical Sector972nd out of 1,048 stocksAnalytical Instruments Industry28th out of 28 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Precipio. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.34% of the outstanding shares of Precipio have been sold short.Short Interest Ratio / Days to CoverPrecipio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Precipio has recently increased by 7.37%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrecipio does not currently pay a dividend.Dividend GrowthPrecipio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRPO. Previous Next 2.8 News and Social Media Coverage News SentimentPrecipio has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Precipio this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precipio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,950.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Precipio is held by insiders.Percentage Held by InstitutionsOnly 9.62% of the stock of Precipio is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Precipio is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precipio is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecipio has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Precipio (NASDAQ:PRPO) StockPrecipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.Read More Receive PRPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter. Email Address PRPO Stock News HeadlinesJanuary 26, 2023 | americanbankingnews.comRichard A. Sandberg Buys 20,000 Shares of Precipio, Inc. (NASDAQ:PRPO) StockJanuary 11, 2023 | finance.yahoo.comPrecipio Signs Another Major HemeScreen™ CustomerJanuary 26, 2023 | PressReach (Ad)Stocks News AnnouncementDon't miss this update. Read the press release about Small Pharma.December 6, 2022 | finance.yahoo.comPrecipio Signs Additional Major HemeScreen™ CustomerNovember 7, 2022 | finance.yahoo.comPrecipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual ConferenceNovember 2, 2022 | finance.yahoo.comPrecipio Announces Third Quarter Shareholder Update CallOctober 18, 2022 | finance.yahoo.comRedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - Yahoo FinanceOctober 18, 2022 | finance.yahoo.comPrecipio, Inc. (NASDAQ:PRPO) Is Expected To Breakeven In The Near FutureJanuary 26, 2023 | PressReach (Ad)Stocks News AnnouncementDon't miss this update. Read the press release about Small Pharma.October 7, 2022 | finance.yahoo.comMedical Device and Diagnostic Reimbursements Expert Joins NDA Partners as Expert Consultant - Yahoo FinanceOctober 7, 2022 | benzinga.comPrecipio And 2 Other Penny Stocks Insiders Are Aggressively Buying - Liberty Star Uranium (OTC:LBSR), Cle - BenzingaSeptember 17, 2022 | finance.yahoo.comPoint of Care (PoC) Infectious Disease Testing Market Surging Over 4X Touching USD 4.22 Billion by 2028 | BlueWeave Consulting - Yahoo FinanceSeptember 17, 2022 | globenewswire.comPoint of Care (PoC) Infectious Disease Testing Market Surging Over 4X Touching USD 4.22 Billion by 2028 | BlueWeave Consulting - GlobeNewswireSeptember 15, 2022 | globenewswire.comPrecipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen - GlobeNewswireSeptember 15, 2022 | finance.yahoo.comPrecipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™September 1, 2022 | reuters.comPRPO.OQ - Precipio Inc | Stock Price & Latest News | ReutersAugust 25, 2022 | globenewswire.comSharon Robins Joins Precipio's Products Division as Senior - GlobeNewswireAugust 24, 2022 | finance.yahoo.comSharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital SalesAugust 16, 2022 | seekingalpha.comPrecipio, Inc. (PRPO) CEO Ilan Danieli on Q2 2022 Results - Earnings Call Transcript - Seeking AlphaAugust 16, 2022 | globenewswire.comPrecipio Launches New 1-Step Technology for all HemeScreen Assays - GlobeNewswireAugust 16, 2022 | finance.yahoo.comPrecipio Launches New 1-Step Technology for all HemeScreen AssaysAugust 10, 2022 | globenewswire.comToni-Ann Mills Joins Precipio's Products Division to Lead - GlobeNewswireAugust 10, 2022 | finance.yahoo.comToni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & DevelopmentAugust 8, 2022 | benzinga.comPrecipio Announces Second Quarter Shareholder Update Call - BenzingaAugust 8, 2022 | finance.yahoo.comPrecipio Announces Second Quarter Shareholder Update CallAugust 7, 2022 | reuters.comPRPO.O - Precipio Inc | Stock Price & Latest News | ReutersJuly 21, 2022 | seekingalpha.comPrecipio to distribute HemeScreen through Fisher Healthcare channel - Seeking AlphaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter. Email Address PRPO Company Calendar Last Earnings11/10/2022Today1/26/2023Next Earnings (Estimated)3/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRPO CUSIPN/A CIK1043961 Webwww.precipiodx.com Phone(203) 787-7888Fax402-452-5401Employees54Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,530,000.00 Net Margins-128.09% Pretax Margin-127.93% Return on Equity-56.55% Return on Assets-44.89% Debt Debt-to-Equity Ratio0.01 Current Ratio1.68 Quick Ratio1.53 Sales & Book Value Annual Sales$8.85 million Price / Sales2.28 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book0.82Miscellaneous Outstanding Shares22,820,000Free Float20,880,000Market Cap$20.20 million OptionableNot Optionable Beta2.16 Key ExecutivesIlan DanieliChief Executive Officer & DirectorAhmed Zaki SabetChief Operating OfficerMatthew GageCFO, Director-Financial Report & AnalysisAyman A. MohamedVice President-Research & DevelopmentOri KarevChief Strategy OfficerKey CompetitorsTalis BiomedicalNASDAQ:TLISIsoPlexisNASDAQ:ISOTelesis BioNASDAQ:DNAYAccelerate DiagnosticsNASDAQ:AXDXRapid Micro BiosystemsNASDAQ:RPIDView All CompetitorsInsiders & InstitutionsRichard A SandbergBought 20,000 shares on 1/20/2023Total: $15,600.00 ($0.78/share)Ilan DanieliBought 16,500 shares on 1/3/2023Total: $9,900.00 ($0.60/share)Ahmed Zaki SabetBought 750 shares on 1/3/2023Total: $450.00 ($0.60/share)Ilan DanieliBought 11,000 shares on 10/3/2022Total: $9,570.00 ($0.87/share)Ahmed Zaki SabetBought 500 shares on 10/3/2022Total: $435.00 ($0.87/share)View All Insider Transactions PRPO Stock - Frequently Asked Questions How have PRPO shares performed in 2023? Precipio's stock was trading at $0.5514 at the start of the year. Since then, PRPO shares have increased by 61.4% and is now trading at $0.89. View the best growth stocks for 2023 here. When is Precipio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023. View our PRPO earnings forecast. How were Precipio's earnings last quarter? Precipio, Inc. (NASDAQ:PRPO) issued its earnings results on Thursday, November, 10th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $2.22 million for the quarter. Precipio had a negative net margin of 128.09% and a negative trailing twelve-month return on equity of 56.55%. When did Precipio's stock split? Precipio shares reverse split on the morning of Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What guidance has Precipio issued on next quarter's earnings? Precipio issued an update on its first quarter 2023 earnings guidance on Wednesday, January, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.34 million-$7.34 million, compared to the consensus revenue estimate of $5.86 million. What other stocks do shareholders of Precipio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Biocept (BIOC), Heat Biologics (HTBX), Portola Pharmaceuticals (PTLA), iBio (IBIO), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Co-Diagnostics (CODX), Inpixon (INPX) and Jaguar Health (JAGX). What is Precipio's stock symbol? Precipio trades on the NASDAQ under the ticker symbol "PRPO." How do I buy shares of Precipio? Shares of PRPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Precipio's stock price today? One share of PRPO stock can currently be purchased for approximately $0.89. How much money does Precipio make? Precipio (NASDAQ:PRPO) has a market capitalization of $20.31 million and generates $8.85 million in revenue each year. The biotechnology company earns $-8,530,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. How can I contact Precipio? Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The official website for the company is www.precipiodx.com. The biotechnology company can be reached via phone at (203) 787-7888, via email at investors@precipiodx.com, or via fax at 402-452-5401. This page (NASDAQ:PRPO) was last updated on 1/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.